Form SC 13G/A Theravance Biopharma, Filed by: VANGUARD GROUP INC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Rescue work underway after quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Leerink Partners Reiterates Market Perform Rating on Theravance Biopharma (TBPH)
November 13, 2024 9:39 AM ESTLeerink Partners analyst David Risinger reiterated a Market Perform rating and $10.00 price target on Theravance Biopharma (NASDAQ: TBPH).
The analyst comments "TBPH reported strong 3Q24 results, including total revenue 12% above consensus and operating income 13% above, but EPS 5% below largely due a non-cash impairment... More
